Nikolaas De Neve

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Alexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al. · The Lancet Respiratory Medicine · 2022 · 131 citations · Full text

Critical Care Medicine, Clinical Infectious Disease, Anti-c5a Antibody +6

Influence of Administration Rate on Propofol Plasma–Effect Site Equilibration

Michel Struys, Marc Coppens, Nikolaas De Neve et al. · Anesthesiology · 2007 · 110 citations

Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: A case series

Diederik K. Van Sassenbroeck, Nikolaas De Neve, Peter De Paepe et al. · Clinical Toxicology · 2007 · 49 citations

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

Elisabeth De Leeuw, Karel Van Damme, Jozefien Declercq et al. · Respiratory Research · 2022 · 22 citations · Full text

Serial measurement of circulating calprotectin as a prognostic biomarker in COVID-19 patients in intensive care setting

Louis Nevejan, Thomas Strypens, Mathias Van Nieuwenhove et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 2022 · 22 citations · Full text